查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1836959

家禽疫苗市场按产品类型、物种、给药途径、最终用户和分销管道划分－2025-2032年全球预测

Poultry Vaccine Market by Product Type, Species, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，家禽疫苗市场规模将成长 41.6 亿美元，复合年增长率为 8.10%。

主要市场统计数据
基准年2024年 22.3亿美元
预计年份：2025年 24.1亿美元
预测年份：2032年 41.6亿美元
复合年增长率 (%) 8.10%

本书以简洁、权威且全面的方式，审视了不断发展的家禽疫苗生态系统，并将科学创新、生产需求和商业优先事项联繫起来。

受科学创新、生产模式变革和生物安全期望不断提高的驱动，家禽疫苗领域正迅速发展。本执行摘要总结了影响全球家禽系统疫苗研发和部署的关键主题，为领导者提供了一个连结科学、政策和商业的综合观点。本执行摘要影响疫苗研发者、经销商和家禽生产商决策优先事项的技术发展轨迹、监管变化、供应链动态和终端用户行为。

近年来，重组技术和精准递送机制的进步开始重新定义疫苗接种计画的风险效益考量。同时，生产商被迫采用兼顾有效性、成本效益和与集约化生产系统相容性的解决方案。因此，研发和商业性活动正转向可扩展、适应不断变化的病原体环境并与数位健康监测系统整合的平台。引言部分概述了变革性转变、贸易动态、细分市场细微差别、区域格局、竞争定位和建议措施如何相互交织，并体现在为家禽疫苗价值链各相关人员制定的稳健战略规划中，从而为后续章节奠定了基础。

科学、监管和营运创新如何融合，加速家禽系统平台多样化和疫苗综合策略的实施

现代家禽疫苗接种格局正受到多种融合变革力量的重塑，这些力量在加速创新的同时，也暴露出系统性脆弱性。首先，平台多元化发展势头强劲，重组技术和核酸技术正从实验阶段走向商业化应用。与传统的减毒或灭活疫苗相比，这种转变能够产生更具针对性的免疫反应，并缩短研发週期，从而改变疫苗研发管线和研发者的投资策略。

其次，给药方式的创新正在改变农场应用的动态。非侵入性给药途径，例如气雾剂和优化的口服製剂，提高了大规模畜群给药的便利性，并减轻了劳动力负担。第三，监管环境正在逐步演变以适应新型生技药品，这促使一些司法管辖区制定更统一的框架，而另一些司法管辖区则存在间歇性的不确定性。这种监管差异促使研发人员设计具有跨境适用性的平台。

第四，数位化工具和诊断技术与疫苗接种策略的结合日益紧密，使得即时监测免疫反应和疫情讯号成为可能。最后，对动物福利和抗菌药物管理的日益重视，正推动疫苗作为预防性卫生手段和抗生素治疗的替代方案，发挥越来越重要的作用。综上所述，这些变化显示家禽养殖业正在转向一个更聪明、更一体化的疫苗接种生态系统。

关税贸易紧张局势如何推动疫苗价值链的供应链重组、区域生产策略与物流优化

近期源自美国的累积关税措施累积起来，为疫苗生产商、供应商和分销网络带来了复杂的挑战和战略曲折点。这些关税提高了依赖进口的製造商某些原料和成品的到岸成本，促使供应链重组，并凸显了采购韧性的重要性。为此，许多相关人员加快了供应商资格认证流程，并积极寻找具备相应品质和监管资格的区域供应商，以降低关税波动带来的风险。

此外，关税主导的成本压力凸显了低温运输优化和库存管理的重要性。物流能力强的公司能够透过优化运输整合、重新谈判货运条款以及延长前置作业时间週期来平稳采购週期，从而抵御短期成本衝击。相反，规模较小的製造商和独立经销商则面临利润率下降的困境，这促使他们寻求策略伙伴关係、联合生产以及选择性的垂直整合，以维持供应管道的畅通和连续性。

贸易政策的调整也加速了关于近岸外包和区域製造中心作为应对关税风险的长期解决方案的讨论。投资者和企业高管正在评估对本地生产能力进行资本投资与跨境贸易持续疲软之间的权衡。同时，随着各司法管辖区调整进口审查流程，监管合规和品质保证仍然至关重要，这凸显了在关税相关干扰下，为维持跨境疫苗供应，透明的文件和统一的标准必不可少。

一个多维度细分框架，用于识别产品平台选择、交付方式、物种特异性需求和分销管道，以製定有针对性的策略。

细分市场层面的差异化对于理解家禽疫苗领域的市场动态和投资重点至关重要。按产品类型进行细分后发现，虽然灭活疫苗和减毒活病毒疫苗等传统平台在安全性和有效性已得到验证的领域仍发挥着重要作用，但重组疫苗因其模组化和适应性而备受关注。在重组疫苗中，mRNA平台、蛋白质次单元构建体和病毒载体系统分别代表不同的研发管道和生产​​模式。病毒载体本身也体现了进一步的技术差异，腺病毒、甲病毒和痘病毒等载体骨架各自具有特异性的免疫抗原性和生产特性，从而影响研发者的选择和最终用户的适用性。

鸡、鸭和火鸡的物种划分会影响抗原的选择、给药方式和疫苗接种方案。给药途径是另一个关键因素。当需要精确给药和获得全身免疫力时，肌肉注射或皮下注射仍然是主流；而口服和喷雾途径（包括气溶胶和雾化喷雾）则更适合大量给药和劳动力有限的场所。最终用户划分区分了家庭养殖、商业农场和研究机构。商业肉鸡和蛋鸡养殖场需要可扩展、经济高效的解决方案，并能整合到高通量生产系统中；而家庭养殖则更注重易用性和对低温运输的依赖性。电商平台和製造商网站等线上管道覆盖面更广，使用更便捷；政府和私人兽医诊所提供临床监督和产品管理；连锁和独立兽药店则方便社区居民获取疫苗和照护现场服务。这些相互作用的细分维度创建了一个多维框架，用于优先考虑研发投资、调整商业化策略以及设计符合最终用户需求和商业现实的经销伙伴关係。

区域间生产规模、监管方式和物流现实的差异将如何影响疫苗偏好和全球部署策略

区域动态将对家禽生产系统中的疫苗研发重点、采购行为、监管方式和流通结构产生至关重要的影响。美洲地区是一个成熟的商业家禽产业，其特点是生物安全通讯协定高度整合、自动化管理技术广泛应用以及对生产力指标的高度重视。在此背景下，创新主要由规模效益、监管信心以及商业生产者投资于能够带来可预测的性能和禽群健康回报的高效平台的意愿所驱动。

欧洲、中东和非洲的疫苗接种环境各不相同，监管协调程度和资源可用性也存在差异。在一些欧洲市场，严格的法律规范和健全的动物福利标准为获得许可、特性明确的疫苗以及全面的监测计划提供了支持。而在中东和非洲的部分地区，疫苗接种策略必须兼顾物流限制、分散的低温运输和多样化的生产体系，因此对耐热配方和便捷的给药方式的需求日益增长。

亚太地区拥有一些发展最快的生产系统和密度极高的家禽养殖场，因此，为了应对地方性和新出现的威胁，需要高度重视可扩展的交付机制、快速反应平台以及针对特定区域的抗原组合。跨境贸易、密集的生产群集以及政府在疾病防治方面的大力投入，使得迫切需要能够大规模部署且符合当地法规和生产能力的适应性疫苗解决方案。在所有地区，地方政策的变化、对通用感染疾病风险的认知以及独特的生产需求都在影响采购时间表和产品性能预期。

竞争定位和伙伴关係策略揭示了传统製造商和生物技术创新者如何塑造疫苗供应和附加价值服务。

家禽疫苗产业的竞争格局由传统生技药品专家、生物技术创新者和灵活的本土开发商组成，各方都凭藉其平台专长、分销网络和监管资料库占据着战略地位。历史悠久的疫苗生产商拥有大规模生产、检验的冷链物流和庞大的安全低温运输优势，这些优势有助于获得监管部门的核准并增强商业客户的信心。同时，专注于重组和核酸平台的生物技术参与企业正在再形成创新前沿，他们展现出更快的候选疫苗迭代速度、平台模组化和跨病原体适应性等潜力。

与研究机构和商业组织的科学研究合作加速了转换管道的拓展，而联合生产和授权协议则扩大了产能和地理覆盖范围。分销策略涵盖了从与高度一体化市场中的生产商直接交易，到与临床监测至关重要的市场中的兽医诊所和药房建立通路合作关係。策略性差异化因素包括专有的佐剂技术、耐热创新以及能够降低给药复杂性的高效递送系统。此外，投资于数据整合（将疫苗接种事件与畜群健康记录和诊断结果关联起来）的公司，能够提供增值服务，透过附加价值服务和分析来加深客户关係并创造稳定的收益来源。

企业应采取具体、优先的行动，以加速平台适应性，增强供应链韧性，并扩大在各种生产系统中的商业性应用。

产业领导者可以采取多项切实可行的措施来增强韧性、加速创新转型并扩大其在禽类市场的商业性影响力。首先，应在其开发平臺中优先考虑平台无关性功能，以实现更快的抗原交换和跨病原体覆盖。其次，应投资优化给药系统，包括气溶胶、喷雾和口服给药，以降低给药成本，并扩大其在劳动力紧张、高密度生产系统中的应用。

第三，我们将透过多元化原料来源、认证本地契约製造以及扩大耐热产品线来增强供应链韧性，从而降低低温运输的依赖。第四，我们将寻求结合技术创新和分销能力的策略伙伴关係，例如与诊断服务提供者达成许可、联合生产和数据共用协议，以建立闭环健康解决方案。第五，我们将积极与封闭式和产业协会合作，支持统一的申请文件，并为平台技术建立灵活的核准管道。最后，我们将透过提供一系列服务（包括培训、监测和结果分析），使商业模式与终端用户的实际情况相符，从而将产品功效转化为商业价值，并帮助不同规模和产能的生产商证明其疫苗投资的合理性。实施这些措施将有助于加快产品上市速度，提高产品普及率，并增强各个生产基地的长期永续性。

我们透明、依证的调查方法结合了专家访谈、文献三角验证和情境压力测试，以引导策略结论。

本执行执行摘要的研究是基于结构化的多源资讯来源调查方法，旨在得出可复製的洞见，并为相关人员提供切实可行的建议。一级资讯来源二级资讯来源同行评审的科学文献、监管指导文件、行业白皮书和供应链物流分析，以验证趋势并检验营运限制。

此分析方法结合了定性综合分析和基于情境的压力测试，旨在探讨贸易和监管变化对供应连续性和产品部署的影响。此方法强调透过多方面的证据交叉检验结论，以减少偏差，确保研究结果反映实际运作而非主观臆断。资料缺失，特别是涉及专有临床效能指标和商业性机密安排的资料缺失，会造成一定的限制。为弥补这些不足，调查方法优先考虑假设的透明度、资料来源的记录，并建议进行有针对性的后续研究，以深入挖掘需要定量检验或客製化本地资讯的细分领域。

策略结论：强调综合技术、商业和供应链弹性措施对于实现疫苗影响至关重要。

目前家禽疫苗接种的发展轨迹为能够将技术创新与切实可行的分销和生产策略相结合的相关人员提供了明确的机会。重组平台和先进的递送方法不再是边缘技术，而是成为生产者和监管机构思考疾病预防和生产连续性的核心要素。同时，不断变化的贸易政策和物流限制凸显了建构具有韧性的供应链架构和灵活的商业化模式的必要性，这些架构和模式能够适应突发性中断和长期结构性变化。

因此，决策者应在短期营运效益（例如耐热性和简化管理）与长期平台开发（能够快速应对新出现的病原体）之间取得平衡。跨部门合作，例如官民合作关係以及与诊断和数位健康服务提供者的合作，是将疫苗效力转化为可衡量的群体健康结果的关键。透过协调研发重点、监管参与和分销策略，相关人员可以加速从概念验证验证创新到在实践中广泛应用的解决方案的转化，从而提高生物安全性和生产商的盈利。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 快速部署基于mRNA的家禽疫苗，以增强广谱病毒保护
  • 精准的卵内疫苗接种机器人整合可减少人工操作和剂量误差
  • 一种耐热的新城疫疫苗的出现，使得向偏远地区分发疫苗成为可能。
  • 开发同时针对禽流感和球虫的多效价载体疫苗
  • 实施基于区块链的疫苗完整性追踪低温运输监控系统
  • 加大对奈米颗粒佐剂的研究投入，以增​​强蛋鸡的黏膜免疫力。
  • 东协协调监管，加速新疫苗紧急使用授权

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 家禽疫苗市场（依产品类型划分）

  • DNA
  • 惰性
  • 减毒活活病毒疫苗
  • 重组
    • mRNA
    • 蛋白质次单元
    • 病毒载体
      • 腺病毒
      • 甲病毒
      • 痘病毒
  • 次单元

9. 家禽疫苗市场（按类型划分）

  • 鸡肉
  • 鸭子
  • 火鸡

10. 家禽疫苗市场依给药途径划分

  • 注射
    • 肌肉注射
    • 皮下
  • 口服
  • 喷
    • 气雾剂
    • 喷

第十一章 家禽疫苗市场（依最终用户划分）

  • 家庭花园
  • 商业农场
    • 肉鸡养殖场
    • 蛋鸡农场
  • 研究所

12. 家禽疫苗市场依分销管道划分

  • 线上通路
    • 电子商务市场
    • 製造商网站
  • 兽医诊所
    • 公立医院
    • 私立医院
  • 兽药
    • 连锁药局
    • 独立药房

13. 各地区家禽疫苗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 家禽疫苗市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国家禽疫苗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Merck & Co., Inc.
    • Zoetis Inc.
    • Boehringer Ingelheim Animal Health GmbH
    • Ceva Sante Animale SA
    • Elanco Animal Health Incorporated
    • HIPRA, SAU
    • Virbac SA
    • Indian Immunologicals Limited
    • Vaxxinova Group BV
    • Phibro Animal Health Corporation
Product Code: MRR-0375F3EA9C41

The Poultry Vaccine Market is projected to grow by USD 4.16 billion at a CAGR of 8.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.23 billion
Estimated Year [2025] USD 2.41 billion
Forecast Year [2032] USD 4.16 billion
CAGR (%) 8.10%

A concise and authoritative synthesis of the evolving poultry vaccine ecosystem connecting scientific innovation, production imperatives, and commercial priorities

The poultry vaccine landscape is undergoing rapid evolution driven by scientific innovation, changing production models, and heightened biosecurity expectations. This executive summary synthesizes critical themes shaping vaccine development and deployment across global poultry systems, offering leaders a consolidated perspective that bridges science, policy, and commerce. The narrative focuses on technological trajectories, regulatory inflections, supply chain dynamics, and end-user behavior that together define decision-making priorities for vaccine developers, distributors, and poultry producers.

In recent years, advancements in recombinant technologies and precision delivery mechanisms have begun to redefine the risk-benefit calculus for vaccination programs. Concurrently, producers face increasing pressure to adopt solutions that balance efficacy, cost efficiency, and operational compatibility with intensive production systems. As a result, research and commercial efforts are shifting toward platforms that can be scaled, adapted to shifting pathogen landscapes, and integrated with digital health monitoring systems. The introduction frames subsequent sections by outlining how transformative shifts, trade dynamics, segmentation nuances, regional patterns, competitive positioning, and recommended actions intersect to inform robust strategic planning for stakeholders across the poultry vaccine value chain.

How converging scientific, regulatory, and operational innovations are accelerating platform diversification and integrated vaccination strategies across poultry systems

The contemporary landscape of poultry vaccination is being reshaped by several convergent transformative forces that accelerate innovation while exposing systemic vulnerabilities. First, platform diversification has gained momentum, with recombinant approaches and nucleic acid technologies moving from experimental stages toward commercial viability. This shift is enabling more targeted immune responses and shorter development cycles relative to classical attenuated or inactivated approaches, altering vaccine pipelines and developer investment strategies.

Second, delivery innovations are changing adoption dynamics on farms. Non-invasive routes such as aerosolized sprays and optimized oral formulations are improving ease of administration for large flocks and reducing labor burdens, which in turn is producing stronger demand from commercial producers seeking operational efficiencies. Third, regulatory landscapes are progressively evolving to accommodate novel biologics, prompting more harmonized frameworks in some jurisdictions while creating intermittent uncertainty in others. This regulatory heterogeneity incentivizes developers to design platforms with cross-border adaptability.

Fourth, digital tools and diagnostics are increasingly linked to vaccination strategies, enabling real-time monitoring of immune response and outbreak signals, and thereby making vaccination decisions more data-driven. Finally, heightened emphasis on animal welfare and antimicrobial stewardship is pushing vaccines to the forefront as both preventive health tools and alternatives to therapeutic antibiotic use. Collectively, these shifts indicate a transition toward smarter, more integrated vaccination ecosystems in poultry production.

How tariff-driven trade frictions have catalyzed supply chain reconfiguration, regional production strategies, and logistics optimization across the vaccine value chain

The cumulative impact of recent tariff actions originating from the United States has introduced a complex set of headwinds and strategic inflection points for vaccine producers, suppliers, and distribution networks. Tariff measures have increased the landed cost of selected inputs and finished goods for import-dependent manufacturers, prompting supply chain reconfiguration and an increased emphasis on sourcing resilience. In response, many stakeholders have accelerated supplier qualification processes and explored regional suppliers with compatible quality and regulatory credentials to mitigate exposure to tariff volatility.

Moreover, tariff-driven cost pressures have amplified the importance of cold-chain optimization and inventory management. Organizations with robust logistics capabilities have been able to absorb short-term cost shocks by streamlining transport consolidation, renegotiating freight terms, and leveraging longer lead times to smooth procurement cycles. Conversely, smaller manufacturers and independent distributors have experienced margin compression, which in turn has encouraged strategic partnerships, co-manufacturing arrangements, and selective vertical integration to preserve access and continuity of supply.

Trade policy adjustments have also accelerated conversations about nearshoring and regional manufacturing hubs as long-term solutions to tariff risk. Investors and executives are increasingly evaluating the trade-offs between capital expenditure for localized capacity and the ongoing softening of cross-border trade flows. In parallel, regulatory compliance and quality assurance remain pivotal as jurisdictions adapt their import-review processes, underscoring the need for transparent documentation and harmonized standards to sustain cross-border vaccine availability despite tariff-related disruptions.

A multidimensional segmentation framework that clarifies product platform choice, delivery modalities, species-specific needs, and distribution pathways for targeted strategies

Segment-level differentiation is central to understanding adoption dynamics and investment priorities across the poultry vaccine landscape. Product type segmentation reveals that traditional platforms such as inactivated and live attenuated vaccines continue to play key roles where established safety and efficacy profiles exist, while recombinant categories are attracting substantial attention for their modularity and adaptability. Within recombinant approaches, mRNA platforms, protein subunit constructs, and viral vector systems demonstrate distinct development pathways and manufacturing footprints. Viral vectors themselves show further technical differentiation across adenovirus, alphavirus, and poxvirus backbones, each bringing specific immunogenic and production characteristics that influence developer choice and end-user suitability.

Species segmentation-spanning chickens, ducks, and turkeys-affects antigen selection, delivery methods, and vaccination schedules because each species presents unique husbandry practices and disease exposure patterns. Route of administration is another critical axis: injectable formats, delivered intramuscularly or subcutaneously, remain prevalent where precise dosing and systemic immunity are priorities, while oral and spray routes, including aerosol and fogging spray modalities, offer practical advantages for mass administration and labor-constrained operations. End-user segmentation distinguishes backyard operations, commercial farms, and research institutions, with commercial broiler and layer farms requiring scalable, cost-effective solutions that integrate into high-throughput production systems, whereas backyard settings prioritize ease of use and minimal cold-chain dependency. Distribution channel segmentation complements these distinctions by shaping access and service models; online channels through e-commerce marketplaces and manufacturer websites offer broader reach and convenience, veterinary hospitals-both government and private-provide clinical oversight and product stewardship, and veterinary pharmacies, whether chain or independent, facilitate localized access and point-of-care advice. These interacting segmentation dimensions create a multidimensional framework for prioritizing R&D investments, tailoring commercialization strategies, and designing distribution partnerships that align with end-user needs and operational realities.

How diverse regional production intensities, regulatory approaches, and logistical realities shape vaccine preferences and deployment strategies globally

Regional dynamics exert a defining influence on vaccine development priorities, procurement behavior, regulatory approaches, and distribution architectures across poultry production systems. The Americas region is characterized by a mature commercial poultry industry with advanced integration of biosecurity protocols, broad use of automated administration technologies, and a strong emphasis on productivity metrics. In this context, innovation is driven by scale efficiencies, regulatory reliability, and commercial producers' willingness to invest in high-efficacy platforms that deliver predictable returns in performance and flock health.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization varies and resource availability ranges widely. In several European markets, stringent regulatory frameworks and strong animal welfare norms favor licensed, well-characterized vaccines and comprehensive surveillance programs. In parts of the Middle East and Africa, vaccination strategies must reconcile logistical constraints, fragmented cold chains, and diverse production systems, which increases demand for thermostable formulations and simplified delivery options.

Asia-Pacific hosts some of the fastest-evolving production systems and high-density poultry populations, driving intensive focus on scalable delivery mechanisms, rapid-response platforms, and regionally tailored antigen panels to address endemic and emerging threats. Cross-border trade, dense production clusters, and strong governmental investment in disease control amplify the urgency for adaptable vaccine solutions that can be deployed at scale while aligning with local regulatory and manufacturing capacities. Across all regions, regional policy shifts, zoonotic risk awareness, and localized production imperatives influence procurement timelines and product performance expectations.

Competitive positioning and partnership strategies that reveal how legacy manufacturers and biotech innovators are shaping vaccine availability and value-added services

Competitive dynamics in the poultry vaccine sector reflect a mix of legacy biologics specialists, biotech innovators, and nimble regional developers, each occupying strategic positions based on platform expertise, distribution reach, and regulatory track record. Established vaccine manufacturers retain advantages in large-scale production, validated cold-chain logistics, and extensive safety databases that ease regulatory approvals and reassure commercial customers. At the same time, biotech entrants focusing on recombinant and nucleic acid platforms are reshaping the innovation frontier by demonstrating faster candidate iteration, platform modularity, and potential for cross-pathogen adaptability.

Partnership models are increasingly prominent; collaborations between research institutions and commercial entities accelerate translational pathways, while co-manufacturing and licensing agreements expand production capacity and geographic reach. Distribution strategies vary from direct-to-producer engagement in highly integrated markets to channel partnerships with veterinary hospitals and pharmacies in markets where clinical oversight is crucial. Strategic differentiators include proprietary adjuvant technologies, thermostability innovations, and validated delivery systems that reduce administration complexity. In addition, companies investing in data integration-linking vaccination events with flock health records and diagnostic outcomes-are positioned to offer value-added services that deepen customer relationships and create sticky revenue streams through service subscriptions and analytics.

Concrete and prioritized measures for companies to accelerate platform adaptability, strengthen supply resilience, and expand commercial adoption across diverse production systems

Industry leaders can adopt several actionable steps to strengthen resilience, accelerate innovation translation, and expand commercial impact across poultry markets. First, prioritize platform-agnostic capabilities in development pipelines to enable faster antigen swaps and cross-pathogen responsiveness; modular platforms reduce time and cost to adapt to emergent disease signals without compromising regulatory compliance. Second, invest in delivery system optimization, including aerosol, fogging, and oral modalities, to lower administration costs and increase adoption in high-density production systems where labor constraints are acute.

Third, reinforce supply chain resilience by diversifying input sources, qualifying regional contract manufacturers, and expanding thermostable product lines to reduce cold-chain dependence. Fourth, pursue strategic partnerships that combine technical innovation with distribution strength, such as licensing arrangements, co-manufacturing, and data-sharing agreements with diagnostic providers to create closed-loop health solutions. Fifth, engage proactively with regulators and industry bodies to support harmonized dossiers and to pilot adaptive approval pathways for platform technologies. Finally, align commercial models with end-user realities by offering bundled services-training, monitoring, and outcome analytics-that translate product efficacy into operational value and make vaccination investments easier to justify for producers with differing scales and capacities. Implementing these measures will improve speed-to-market, adoption rates, and long-term sustainability across varied production landscapes.

A transparent evidence-based methodology combining expert interviews, literature triangulation, and scenario stress tests to inform strategic conclusions

The research underpinning this executive summary relies on a structured, multi-source methodology designed to produce replicable insights and to surface practical implications for stakeholders. Primary inputs included in-depth interviews with subject-matter experts across vaccine R&D, veterinary practice, and poultry production, supplemented by technical briefings with developers of recombinant and nucleic acid platforms. Secondary sources encompassed peer-reviewed scientific literature, regulatory guidance documents, industry whitepapers, and supply chain logistics analyses to triangulate trends and validate operational constraints.

Analytical methods combined qualitative synthesis with scenario-based stress testing to explore the ramifications of trade and regulatory shifts on supply continuity and product deployment. The approach emphasized cross-validation of claims through multiple evidence streams to reduce bias and to ensure findings reflect operational realities rather than aspirational projections. Limitations are acknowledged where data gaps exist, particularly around proprietary clinical performance metrics and confidential commercial arrangements. To mitigate this, the methodology prioritized transparency in assumptions, documented data provenance, and recommended targeted follow-up engagements to drill deeper into areas requiring quantitative verification or bespoke local intelligence.

Synthesis of strategic conclusions emphasizing the imperative for integrated technological, commercial, and supply resilience actions to realize vaccine impact

The current trajectory of poultry vaccination signals a clear opportunity for stakeholders who can integrate technological innovation with pragmatic distribution and production strategies. Recombinant platforms and advanced delivery methods are no longer peripheral; they are becoming central to how producers and regulators think about disease prevention and production continuity. At the same time, trade policy shifts and logistical constraints underscore the need for resilient supply architectures and agile commercialization models that can adapt to both acute disruptions and longer-term structural changes.

Decision-makers should therefore balance investments across near-term operational gains-such as thermostability and simplified administration-and longer-term platform development that enables rapid response to emerging pathogens. Cross-sector collaboration, including public-private partnerships and alliances with diagnostic and digital health providers, will be instrumental in converting vaccine efficacy into measurable flock health outcomes. By aligning R&D priorities, regulatory engagement, and distribution strategies, stakeholders can accelerate the transition from proof-of-concept innovations to widely adopted, field-ready solutions that enhance biosecurity and producer profitability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of mRNA-based poultry vaccines to enhance broad-spectrum viral protection
  • 5.2. Integration of precision in ovo vaccination robots to reduce manual labor and dosage errors
  • 5.3. Emergence of thermostable Newcastle disease vaccines enabling distribution in remote regions
  • 5.4. Development of multivalent vector vaccines targeting avian influenza and coccidiosis simultaneously
  • 5.5. Implementation of blockchain-enabled cold chain monitoring systems for vaccine integrity tracking
  • 5.6. Rising investments in nanoparticle adjuvant research to boost mucosal immunity in laying hens
  • 5.7. Regulatory alignment across ASEAN nations to expedite emergency use authorizations for novel vaccines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Poultry Vaccine Market, by Product Type

  • 8.1. DNA
  • 8.2. Inactivated
  • 8.3. Live Attenuated
  • 8.4. Recombinant
    • 8.4.1. mRNA
    • 8.4.2. Protein Subunit
    • 8.4.3. Viral Vector
      • 8.4.3.1. Adenovirus
      • 8.4.3.2. Alphavirus
      • 8.4.3.3. Poxvirus
  • 8.5. Subunit

9. Poultry Vaccine Market, by Species

  • 9.1. Chicken
  • 9.2. Duck
  • 9.3. Turkey

10. Poultry Vaccine Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intramuscular
    • 10.1.2. Subcutaneous
  • 10.2. Oral
  • 10.3. Spray
    • 10.3.1. Aerosol
    • 10.3.2. Fogging

11. Poultry Vaccine Market, by End User

  • 11.1. Backyard Farms
  • 11.2. Commercial Farms
    • 11.2.1. Broiler Farms
    • 11.2.2. Layer Farms
  • 11.3. Research Institutes

12. Poultry Vaccine Market, by Distribution Channel

  • 12.1. Online Channels
    • 12.1.1. E Commerce Marketplaces
    • 12.1.2. Manufacturer Websites
  • 12.2. Veterinary Hospitals
    • 12.2.1. Government Hospitals
    • 12.2.2. Private Hospitals
  • 12.3. Veterinary Pharmacies
    • 12.3.1. Chain Pharmacies
    • 12.3.2. Independent Pharmacies

13. Poultry Vaccine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Poultry Vaccine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Poultry Vaccine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Merck & Co., Inc.
    • 16.3.2. Zoetis Inc.
    • 16.3.3. Boehringer Ingelheim Animal Health GmbH
    • 16.3.4. Ceva Sante Animale S.A.
    • 16.3.5. Elanco Animal Health Incorporated
    • 16.3.6. HIPRA, S.A.U.
    • 16.3.7. Virbac S.A.
    • 16.3.8. Indian Immunologicals Limited
    • 16.3.9. Vaxxinova Group B.V.
    • 16.3.10. Phibro Animal Health Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL POULTRY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPECIES, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPECIES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POULTRY VACCINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL POULTRY VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL POULTRY VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS POULTRY VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL POULTRY VACCINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. POULTRY VACCINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. POULTRY VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. POULTRY VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL POULTRY VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL POULTRY VACCINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL POULTRY VACCINE MARKET SIZE, BY DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL POULTRY VACCINE MARKET SIZE, BY DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL POULTRY VACCINE MARKET SIZE, BY DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL POULTRY VACCINE MARKET SIZE, BY DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL POULTRY VACCINE MARKET SIZE, BY DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL POULTRY VACCINE MARKET SIZE, BY DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL POULTRY VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL POULTRY VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL POULTRY VACCINE MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL POULTRY VACCINE MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL POULTRY VACCINE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL POULTRY VACCINE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL POULTRY VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL POULTRY VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL POULTRY VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL POULTRY VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL POULTRY VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL POULTRY VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL POULTRY VACCINE MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL POULTRY VACCINE MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL POULTRY VACCINE MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL POULTRY VACCINE MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL POULTRY VACCINE MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL POULTRY VACCINE MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL POULTRY VACCINE MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL POULTRY VACCINE MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL POULTRY VACCINE MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL POULTRY VACCINE MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL POULTRY VACCINE MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL POULTRY VACCINE MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL POULTRY VACCINE MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL POULTRY VACCINE MARKET SIZE, BY ADENOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL POULTRY VACCINE MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL POULTRY VACCINE MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL POULTRY VACCINE MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL POULTRY VACCINE MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL POULTRY VACCINE MARKET SIZE, BY ALPHAVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL POULTRY VACCINE MARKET SIZE, BY ALPHAVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL POULTRY VACCINE MARKET SIZE, BY ALPHAVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL POULTRY VACCINE MARKET SIZE, BY ALPHAVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL POULTRY VACCINE MARKET SIZE, BY ALPHAVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL POULTRY VACCINE MARKET SIZE, BY ALPHAVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL POULTRY VACCINE MARKET SIZE, BY POXVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL POULTRY VACCINE MARKET SIZE, BY POXVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL POULTRY VACCINE MARKET SIZE, BY POXVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL POULTRY VACCINE MARKET SIZE, BY POXVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL POULTRY VACCINE MARKET SIZE, BY POXVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL POULTRY VACCINE MARKET SIZE, BY POXVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHICKEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHICKEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHICKEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHICKEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHICKEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHICKEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL POULTRY VACCINE MARKET SIZE, BY DUCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL POULTRY VACCINE MARKET SIZE, BY DUCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL POULTRY VACCINE MARKET SIZE, BY DUCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL POULTRY VACCINE MARKET SIZE, BY DUCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL POULTRY VACCINE MARKET SIZE, BY DUCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL POULTRY VACCINE MARKET SIZE, BY DUCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL POULTRY VACCINE MARKET SIZE, BY TURKEY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL POULTRY VACCINE MARKET SIZE, BY TURKEY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL POULTRY VACCINE MARKET SIZE, BY TURKEY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL POULTRY VACCINE MARKET SIZE, BY TURKEY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL POULTRY VACCINE MARKET SIZE, BY TURKEY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL POULTRY VACCINE MARKET SIZE, BY TURKEY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL POULTRY VACCINE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL POULTRY VACCINE MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL POULTRY VACCINE MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL POULTRY VACCINE MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL POULTRY VACCINE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL POULTRY VACCINE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL POULTRY VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL POULTRY VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL POULTRY VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL POULTRY VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL POULTRY VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL POULTRY VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL POULTRY VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL POULTRY VACCINE MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL POULTRY VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL POULTRY VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL POULTRY VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL POULTRY VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPRAY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL POULTRY VACCINE MARKET SIZE, BY AEROSOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL POULTRY VACCINE MARKET SIZE, BY AEROSOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL POULTRY VACCINE MARKET SIZE, BY AEROSOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL POULTRY VACCINE MARKET SIZE, BY AEROSOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL POULTRY VACCINE MARKET SIZE, BY AEROSOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL POULTRY VACCINE MARKET SIZE, BY AEROSOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL POULTRY VACCINE MARKET SIZE, BY FOGGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL POULTRY VACCINE MARKET SIZE, BY FOGGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL POULTRY VACCINE MARKET SIZE, BY FOGGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL POULTRY VACCINE MARKET SIZE, BY FOGGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL POULTRY VACCINE MARKET SIZE, BY FOGGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL POULTRY VACCINE MARKET SIZE, BY FOGGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL POULTRY VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL POULTRY VACCINE MARKET SIZE, BY BACKYARD FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL POULTRY VACCINE MARKET SIZE, BY BACKYARD FARMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL POULTRY VACCINE MARKET SIZE, BY BACKYARD FARMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL POULTRY VACCINE MARKET SIZE, BY BACKYARD FARMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL POULTRY VACCINE MARKET SIZE, BY BACKYARD FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL POULTRY VACCINE MARKET SIZE, BY BACKYARD FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL POULTRY VACCINE MARKET SIZE, BY BROILER FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL POULTRY VACCINE MARKET SIZE, BY BROILER FARMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL POULTRY VACCINE MARKET SIZE, BY BROILER FARMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL POULTRY VACCINE MARKET SIZE, BY BROILER FARMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL POULTRY VACCINE MARKET SIZE, BY BROILER FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL POULTRY VACCINE MARKET SIZE, BY BROILER FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL POULTRY VACCINE MARKET SIZE, BY LAYER FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL POULTRY VACCINE MARKET SIZE, BY LAYER FARMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL POULTRY VACCINE MARKET SIZE, BY LAYER FARMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL POULTRY VACCINE MARKET SIZE, BY LAYER FARMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL POULTRY VACCINE MARKET SIZE, BY LAYER FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL POULTRY VACCINE MARKET SIZE, BY LAYER FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL POULTRY VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL POULTRY VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL POULTRY VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL POULTRY VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL POULTRY VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL POULTRY VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL POULTRY VACCINE MARKET SIZE, BY E COMMERCE MARKETPLACES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL POULTRY VACCINE MARKET SIZE, BY E COMMERCE MARKETPLACES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL POULTRY VACCINE MARKET SIZE, BY E COMMERCE MARKETPLACES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL POULTRY VACCINE MARKET SIZE, BY E COMMERCE MARKETPLACES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL POULTRY VACCINE MARKET SIZE, BY E COMMERCE MARKETPLACES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL POULTRY VACCINE MARKET SIZE, BY E COMMERCE MARKETPLACES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL POULTRY VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL POULTRY VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL POULTRY VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL POULTRY VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL POULTRY VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL POULTRY VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL POULTRY VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL POULTRY VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL POULTRY VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL POULTRY VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL POULTRY VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL POULTRY VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL POULTRY VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL POULTRY VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL POULTRY VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL POULTRY VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL POULTRY VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL POULTRY VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL POULTRY VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL POULTRY VACCINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS POULTRY VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS POULTRY VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS POULTRY VACCINE MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS POULTRY VACCINE MARKET SIZE, BY SPRAY, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS POULTRY VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY SPRAY, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY SPRAY, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2025-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 322. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 324. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 326. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD